{"filing":{"accession_number":"0001193125-26-252475","cik":"0001831828","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"vera-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm"},"events":[{"id":7433,"run_id":6532,"accession_number":"0001193125-26-252475","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The disclosure announces alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy, with results expected in Q3 2026 and a planned supplemental BLA submission in Q4 2026. This represents a material regulatory milestone and timeline acceleration for a key clinical program, but does not fit neatly into the more specific event categories (it is neither a completed M\u0026A transaction, a restatement, an executive change, nor a cybersecurity incident). The forward-looking nature and regulatory significance make it material to investors assessing the company's pipeline progress.","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3533,"accession_number":"0001193125-26-252475","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy, with results expected in Q3 2026 and a planned supplemental BLA submission in Q4 2026. This represents a material regulatory milestone and timeline acceleration for a key clinical program, but does not fit neatly into the more specific event categories (it is neither a completed M\u0026A transaction, a restatement, an executive change, nor a cybersecurity incident). The forward-looking nature and regulatory significance make it material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:14:26.320334+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3533,"accession_number":"0001193125-26-252475","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy, with results expected in Q3 2026 and a planned supplemental BLA submission in Q4 2026. This represents a material regulatory milestone and timeline acceleration for a key clinical program, but does not fit neatly into the more specific event categories (it is neither a completed M\u0026A transaction, a restatement, an executive change, nor a cybersecurity incident). The forward-looking nature and regulatory significance make it material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:14:26.320334+00:00","company_name":"Vera Therapeutics, Inc.","ticker":"VERA","filing_date":"2026-06-02"}]}